NAS:IMMU (USA) Also trade in: Germany

Immunomedics Inc

$ 14.8 0.37 (2.56%)
Volume: 1,538,210 Avg Vol (1m): 2,580,261
Market Cap $: 2.83 Bil Enterprise Value $: 2.63 Bil
P/E (TTM): 0.00 P/B: 15.46
Earnings Power Value -3.47
Net Current Asset Value 0.77
Tangible Book 0.96
Projected FCF -3.67
Median P/S Value 0.08
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 4/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 1.86
Cash-To-Debt ranked lower than
73.38% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
IMMU: 1.86
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.33, Med: 10000, Max: 10000
Current: 1.86
0.33
10000
Debt-to-Equity 1.30
Debt-to-Equity ranked lower than
95.80% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
IMMU: 1.3
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -30.1, Med: 0.03, Max: 18.04
Current: 1.3
-30.1
18.04
Debt-to-EBITDA -0.75
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
IMMU: -0.75
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -2.13, Med: -1.68, Max: -0.67
Current: -0.75
-2.13
-0.67
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.39
DISTRESS
GREY
SAFE
Beneish M-Score -7.16
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 11.63%

Profitability & Growth : 2/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -31863.82
Operating Margin ranked lower than
87.88% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
IMMU: -31863.82
Ranked among companies with meaningful Operating Margin only.
N/A
Net Margin % -41708.99
Net Margin ranked lower than
91.67% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
IMMU: -41708.99
Ranked among companies with meaningful Net Margin only.
N/A
ROE % -181.08
ROE ranked lower than
100.00% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
IMMU: -181.08
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -270.91, Med: -36.03, Max: 740.72
Current: -181.08
-270.91
740.72
ROA % -84.54
ROA ranked lower than
88.28% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
IMMU: -84.54
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -139.58, Med: -41.84, Max: 74.44
Current: -84.54
-139.58
74.44
ROC (Joel Greenblatt) % -2005.46
ROC (Joel Greenblatt) ranked lower than
73.17% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
IMMU: -2005.46
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -3207.42, Med: -481.63, Max: 760.43
Current: -2005.46
-3207.42
760.43
3-Year Total Revenue Growth Rate -30.10
3-Year Revenue Growth Rate ranked lower than
76.50% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
IMMU: -34.5
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -56.9, Med: -0.8, Max: 81.6
Current: -34.5
-56.9
81.6
3-Year Total EBITDA Growth Rate -61.30
3-Year EBITDA Growth Rate ranked lower than
87.03% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
IMMU: -50.3
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
N/A
3-Year EPS w/o NRI Growth Rate -51.80
3-Year EPS w/o NRI Growth Rate ranked lower than
90.56% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
IMMU: -51.8
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
N/A

» IMMU's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:IMMU

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325413    SIC : 2835
Compare HKSE:00570 HKSE:01877 NAS:RGEN NAS:FOLD NYSE:BHVN XMAD:ALM NYSE:EBS SHSE:600201 NAS:GBT XKRX:086900 SHSE:600161 SHSE:603233 XBRU:TUB XTER:MOR NAS:ICPT SZSE:002821 TSE:4974 XSWX:IDIA NAS:AGIO NAS:LGND
Traded in other countries IM3.Germany
Address 300 The American Road, Morris Plains, NJ, USA, 07950
Immunomedics Inc is a clinical-stage biopharmaceutical company, based in the United States. The company develops monoclonal antibody-based products for the targeted treatment of cancer and autoimmune disorders, among others. Its portfolio of products under investigation include antibody-drug conjugates that target the tumor-reducing toxic effects of chemotherapeutic treatments. The company's pipeline includes products targeting solid tumors and hematologic malignancies, among other diseases in clinical and preclinical development. The company is marketing specific diagnostic imaging agents to detect bone infections in Europe, Canada, and Australia. The company has subsidiaries in the Netherlands and Germany to manage sales and clinical trials in Europe.

Ratios

Current vs industry vs history
PB Ratio 15.46
PB Ratio ranked lower than
98.34% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
IMMU: 15.46
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 4.31, Med: 10.84, Max: 226.36
Current: 15.46
4.31
226.36
PS Ratio 7400.00
PS Ratio ranked lower than
96.83% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
IMMU: 7400
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 2.96, Med: 41.67, Max: 9605
Current: 7400
2.96
9605
EV-to-EBIT -8.15
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
IMMU: -8.15
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -343.7, Med: -7.2, Max: 418.7
Current: -8.15
-343.7
418.7
EV-to-EBITDA -8.23
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
IMMU: -8.23
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -226.2, Med: -7.3, Max: 393.3
Current: -8.23
-226.2
393.3
EV-to-Revenue 3029.30
EV-to-Revenue ranked lower than
95.20% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
IMMU: 3029.3
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 1.5, Med: 39.8, Max: 8976.1
Current: 3029.3
1.5
8976.1
Current Ratio 7.89
Current Ratio ranked lower than
54.93% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
IMMU: 7.89
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.57, Med: 5.01, Max: 38
Current: 7.89
0.57
38
Quick Ratio 7.89
Quick Ratio ranked lower than
51.96% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
IMMU: 7.89
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.56, Med: 4.89, Max: 37.93
Current: 7.89
0.56
37.93
Days Inventory 0.02
Days Inventory ranked lower than
83.16% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
IMMU: 0.02
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 3.12, Med: 7.6, Max: 451.75
Current: 0.02
3.12
451.75

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -5.80
3-Year Share Buyback Rate ranked higher than
73.51% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
IMMU: -5.8
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -14.6, Med: -5.8, Max: -0.1
Current: -5.8
-14.6
-0.1

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 15.46
Price-to-Tangible-Book ranked lower than
96.76% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
IMMU: 15.46
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 3.09, Med: 10.57, Max: 2290
Current: 15.46
3.09
2290
Price-to-Median-PS-Value 185.00
Price-to-Median-PS-Value ranked lower than
99.26% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
IMMU: 185
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.08, Med: 0.93, Max: 240.13
Current: 185
0.08
240.13
Earnings Yield (Joel Greenblatt) % -12.27
Earnings Yield (Greenblatt) ranked higher than
58.83% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
IMMU: -12.27
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -69.6, Med: -9.4, Max: 18.3
Current: -12.27
-69.6
18.3

More Statistics

Revenue (TTM) (Mil) $ 0.87
EPS (TTM) $ -1.98
Beta 1.59
Volatility % 56.88
52-Week Range $ 11.55 - 27.33
Shares Outstanding (Mil) 191.54

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N